Driven by the intricacy of the illness and the need for individualized treatments, targeted
therapy and biomarker research in thyroid cancer represent an important frontier in …

Theranostics refers to the combination of diagnostic biomarkers with therapeutic agents that
share a specific target expressed by diseased cells and tissues. Nuclear medicine is an …

Thyroid cancer, specifically differentiated thyroid carcinoma (DTC), is one of the most
prevalent endocrine malignancies worldwide. Radioactive iodine therapy (RAIT) using I-131 …

Volumetry is crucial in oncology and endocrinology, for diagnosis, treatment planning, and
evaluating response to therapy for several diseases. The integration of Artificial Intelligence …

Purpose Although most patients with differentiated thyroid carcinoma (DTC) have an
excellent prognosis, a subset will experience radioactive iodine refractory (RAI-R) disease …

Radiopharmaceutical therapy (RPT) has become an effective treatment option for
neuroendocrine tumors (NETs) and castration-resistant prostate cancer and is in clinical …

Precise dosimetry has gained interest for interpreting the response assessments of novel
therapeutic radiopharmaceuticals, as well as for improving conventional radiotherapies such …

There has been a notable global escalation in the incidence of thyroid carcinoma, with a
particularly pronounced surge of 240% in the incidence of papillary thyroid carcinoma over …

Background: In 131I therapies internal dosimetry is crucial for determining the mean
absorbed dose to organs at risk, particularly the bone marrow, which has a dose constraint …

Differentiated thyroid cancer is the most common type of thyroid cancer; the types in this
category are papillary, follicular, and hurthel cell carcinoma. Up to 20% of DTCs will …